AstraZeneca Holds Preliminary Talks with Bristol Myers Squibb on Potential $400 Billion Merger
oncodaily - A deal that could create the world’s fourth-largest drugmaker British pharmaceutical leader AstraZeneca has held confidential, preliminary discussions regarding a potential combination with US rival Bristol Myers Squibb(BMS). A completed […]
AI Summary: AstraZeneca entered preliminary, non-binding talks with Bristol Myers Squibb about a potential $400 billion merger, probing whether combining pipelines and scale could reshape oncology and other businesses. The discussions are early, sparking market speculation and likely regulatory scrutiny as executives weigh strategic synergies against integration complexity and antitrust risk.
Related Stories
Gilead acquires Tubulis in multibillion-dollar push beyond HIV / 4 months
Eli Lilly acquires CrossBridge Bio in oncology deal up to $300M / 4 months
Novartis pays $2B for Synnovation’s next‑gen PI3Kα inhibitor / 5 months
Merck to acquire Terns Therapeutics for $6.7B / 5 months
Novartis buys Myricx Bio to bolster ADC ambitions / 7 wks
Biogen announces $5.6B acquisition of Apellis Pharma / 4 months
Gilead buys Ouro Medicines for about $1.68–1.7B to bolster autoimmune pipeline / 5 months
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Behavioral Health, Public Health, Animal Health, Pediatric Oncology and look for the RSS link.
StackHealth Time Machine